Zota Health Care Ltd
Zota Health Care Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
Guidance rank: #28 of 84 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Zota Health Care Ltd Q1 FY27 key numbers
- Revenue
- Stores typically reach maturity within 12-18 months, with mature stores generating INR4.13 lakh+ GMV/month.
As stated in Zota Health Care Ltd's Q1 FY27 earnings call transcript · published 26 Aug 2026. Reported figures, not investment advice.
The short version
EBITDA margin for FY27 is expected to be higher than FY26 on a full-year basis. EBITDA margin for FY27 is expected to be higher than FY26 on a full-year basis.
From Zota Health Care Ltd's Q1 FY27 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- EBITDA margin for FY27 is expected to be higher than FY26 on a full-year basis.
- Aggressive store expansion planned from Q3 and Q4 FY27, with around 650 store additions targeted for the full year.
- Mature stores (850+ stores) contribute significantly to profitability, offsetting new store expansion impact.
- Stores typically reach maturity within 12-18 months, with mature stores generating INR4.13 lakh+ GMV/month.
- Same-store sales growth (SSG) remains strong, with some cohorts showing 30%+ annualized growth.
- The company expects to become fully cash positive by end of Q4 FY27 or Q1 FY28.
- Marketing initiatives and brand-building expected to drive demand and penetration, supporting revenue growth.
2 more points from Zota Health Care Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Zota Health Care Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Zota Health Care Limited made strategic investments in SKIA and UGO Generics, investing INR 2 crores each; both are in early stages with pilot rollouts beginning and expected progress from next quarter onward.
- The company acquired Globotask IT Consultancy to strengthen internal IT capabilities, enhance data security, reduce reliance on external IT vendors, and achieve cost benefits long-term.
- However, store expansion continues with planned addition of 600-650 stores in the current financial year, indicating ongoing investment in retail footprint and operations.
- Emphasis on brand building and marketing investments, including brand ambassadors, suggests continued strategic capital allocation toward marketing rather than heavy physical asset investments.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Zota Health Care Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Zota Health Care Ltd said on order book & pipeline — free account, 30 seconds.
What the Q1 FY27 call signalled
2 of 3 strong
Zota Health Care Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹199 Cr, net loss ₹26 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Zota Health Care's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjiv.Parant. (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Zota Health Care Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Zota Health Care Ltd Q1 FY27 results?
EBITDA margin for FY27 is expected to be higher than FY26 on a full-year basis. EBITDA margin for FY27 is expected to be higher than FY26 on a full-year basis.
What is Zota Health Care Ltd share price analysis?
Zota Health Care Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of N/A with a market cap of ₹4,882 Cr. Investors should review the full earnings analysis for detailed insights.
Is Zota Health Care Ltd planning capital expenditure?
Zota Health Care Limited made strategic investments in SKIA and UGO Generics, investing INR 2 crores each; both are in early stages with pilot rollouts beginning and expected progress from next quarter onward.
Keep Zota Health Care Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.